AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit margin of ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

Monday was a grim day for a great many stocks, but luckily for its investors, AbbVie (NYSE: ABBV) wasn't one of them. The ...

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $212.73, a high ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tim Anderson from Bank of ...

The annualized dividend paid by AbbVie is $6.56/share, currently paid in quarterly installments, and its most recent dividend ...

AbbVie Inc. closed 15.68% short of its 52-week high of $207.32, which the company achieved on October 31st.

We recently published a list of the 12 Best Stocks to Buy in 2025 for Beginners. In this article, we are going to take a look ...

Research analysts at William Blair decreased their FY2025 earnings per share (EPS) estimates for shares of AbbVie in a note ...

William Blair reduced their FY2024 EPS estimates for shares of AbbVie in a research note issued on Tuesday, January 21st.